JPMorgan downgraded Allogene Therapeutics (ALLO) to Underweight from Neutral without a price target The firm says the company’s decision to drop CD52’s component in the cema-cel program was “rational and truly unavoidable given the fatal event.” It believes adoption of cema-cel will take time, making it difficult to remain optimistic on the shares in the near-term.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics’ Promising Study on LBCL Treatment with Cema-cel
- Allogene Therapeutics Earnings Call: Progress Amid Challenges
- Allogene Therapeutics management to meet with Piper Sandler
- Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges
- Promising Pipeline and Strategic Advancements Drive Buy Rating for Allogene Therapeutics